Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kowey, P. R.
Right arrow Articles by Stohler, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kowey, P. R.
Right arrow Articles by Stohler, J. L.
(Chest. 1988;93:54-59.)
© 1988 American College of Chest Physicians

Safety and Efficacy of Amiodarone

The Low-Dose Perspective

Peter R. Kowey M.D., F.C.C.P.1; Ted D. Friehling M.D., F.C.C.P.1; Roger A. Marinchak M.D.1; Antoinette M. Sulpizi M.D.1; and Jane L. Stohler R.N.1

1 From the Cardiac Arrhythmia Service, Department of Medicine, Medical College of Pennsylvania, Philadelphia

Amiodarone has been reported to be a remarkably safe and effective drug in the European and South American experience but American investigators have published conflicting data. Since this disparity may be explained by a different dosing schedule, we prospectively evaluated the safety and efficacy of a low dose regimen in a group of 68 patients with cardiac arrhythmia resistant to conventional therapy, of whom 57 had manifested either ventricular tachycardia or fibrillation. All were loaded either intravenously (17) or orally, and maintained on an oral dose of 200 to 600 mg/day (mean daily dose 317±114 mg) and followed for 4 to 58 months (22±11). Results indicated that amiodarone was a safe and effective antiarrhythmic drug when used in lower doses.

Submitted on February 17, 2007
Accepted on July 6, 2007




This article has been cited by other articles:


Home page
 ChestHome page
M. C. Ott, A. Khoor, J. P. Leventhal, T. E. Paterick, and C. D. Burger
Pulmonary Toxicity in Patients Receiving Low-Dose Amiodarone
Chest, February 1, 2003; 123(2): 646 - 651.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
I. Dimopoulou, K. Marathias, M. Daganou, S. Prapas, G. Stavridis, M. Khoury, S. Geroulanos, and D. V. Cokkinos
LOW-DOSE AMIODARONE-RELATED COMPLICATIONS AFTER CARDIAC OPERATIONS
J. Thorac. Cardiovasc. Surg., July 1, 1997; 114(1): 31 - 37.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American College of Chest Physicians.